Literature DB >> 15597168

[Sodium selenite reduces acute radiogenic damage of the rat parotid glands during fractionated irradiation].

C Sagowski1, S Wenzel, S Tesche, L Jenicke, W Kehrl, K Roeser, F U Metternich.   

Abstract

BACKGROUND: In vitro studies show that sodium selenite is a potential radioprotector in normal cell cultures, but not tumor cells. The aim of this study was to evaluate the cytoprotective potency of sodium selenite during conventional fractionated irradiation of rat salivary glands, but also on tumor response and metastasis frequency of rhabdomyosarcomas R1H.
METHOD: The head-neck area of male WAG/RijH rats and the tumor in the flank were irradiated with (60)Co-gamma-rays (60 Gy/30 fractions/6 weeks). Sodium selenite (15 microg/kg body weight) was applied through a venous port 30 min before irradiation. Rats of a control group were treated in the same manner with an equal volume of physiologic sodium chloride. In the course of treatment the salivary glands were extirpated at different stages and examined histopathologically. The evaluation of the gland function was performed prior to and after radiotherapy by sialoscintigraphy. Tumor volume was measured during irradiation and plotted in tumor-volume curves. Rat body weight was determined sequentially to estimate the general constitution of the animal during the treatment.
RESULTS: Irradiation caused dose-dependent damage in the salivary glands. Intra- and intercellular edema (16 Gy), vacuolization (30 Gy), degranulation (46 Gy), and necrosis of the acinar cells (60 Gy) occurred. Sodium selenite delayed the development of the described damage, and the amount of necrotic acinar cells after the application of 60 Gy was reduced (control: 75% vs sodium selenite 30%), confirmed by the sialoscintigraphic results. The loss in gland function in the control group was 44% vs 74% (p<0.05) in the sodium selenite group. Sodium selenite had no influence on the response of R1H tumors to radiation and general constitution.
CONCLUSIONS: Based on morphological and sialoscintigraphic findings, a cytoprotective effect on acute toxicity of rat salivary glands could be detected under irradiation with synchronous application of sodium selenite. In addition, no effects on tumor response and metastasis frequency were observed. The general animal constitution was not affected by additional medication with sodium selenite during irradiation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15597168     DOI: 10.1007/s00106-003-0992-x

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  19 in total

1.  [Selenium in oncology. Really "noli nocere"?].

Authors:  R Mücke; J Büntzel; K G Schönekaes; O Micke
Journal:  Internist (Berl)       Date:  2003-02       Impact factor: 0.743

2.  [Histomorphologic and salivary gland scintigraphic findings in radiation-induced sialadenitis due to fractionated irradiation of the head and neck region of rats. A model for evaluating potentially radioprotective substances].

Authors:  C Sagowski; S Wenzel; I Riehle; S Tesche; L Jenicke; F Zywietz; K Roeser; F U Metternich
Journal:  HNO       Date:  2004-01       Impact factor: 1.284

3.  Xenopus poly (A) binding protein maternal RNA is localized during oogenesis and associated with large complexes in blastula.

Authors:  K E Schroeder; H J Yost
Journal:  Dev Genet       Date:  1996

4.  A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.

Authors:  K S Chao; J O Deasy; J Markman; J Haynie; C A Perez; J A Purdy; D A Low
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-03-15       Impact factor: 7.038

5.  Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques.

Authors:  K S Chao; N Majhail; C J Huang; J R Simpson; C A Perez; B Haughey; G Spector
Journal:  Radiother Oncol       Date:  2001-12       Impact factor: 6.280

6.  Combined modality radioprotection: the use of glucan and selenium with WR-2721.

Authors:  M L Patchen; T J MacVittie; J F Weiss
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-05       Impact factor: 7.038

7.  Serum selenium levels in patients with head and neck cancer.

Authors:  S P S Yadav; Amit Gera; Ishwar Singh; Rakesh Chanda
Journal:  J Otolaryngol       Date:  2002-08

8.  Selenium in the treatment of radiation-associated secondary lymphedema.

Authors:  Oliver Micke; Frank Bruns; Ralph Mücke; Ulrich Schäfer; Michael Glatzel; Alexander F DeVries; Klaus Schönekaes; Klaus Kisters; Jens Büntzel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-05-01       Impact factor: 7.038

9.  Selenium pretreatment enhances the radioprotective effect and reduces the lethal toxicity of WR-2721.

Authors:  J F Weiss; R L Hoover; K S Kumar
Journal:  Free Radic Res Commun       Date:  1987

10.  Radical scavenging activity and cytotoxicity of ferulic acid.

Authors:  Takako Ogiwara; Kazue Satoh; Yoshinori Kadoma; Yukio Murakami; Senwa Unten; Toshiko Atsumi; Hiroshi Sakagami; Seiichiro Fujisawa
Journal:  Anticancer Res       Date:  2002 Sep-Oct       Impact factor: 2.480

View more
  3 in total

1.  Radiation protection following nuclear power accidents: a survey of putative mechanisms involved in the radioprotective actions of taurine during and after radiation exposure.

Authors:  Olav Albert Christophersen
Journal:  Microb Ecol Health Dis       Date:  2012-02-01

Review 2.  Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients.

Authors:  G Dennert; M Horneber
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

3.  Sodium selenite is a potent radioprotector of the salivary glands of the rat: acute effects on the morphology and parenchymal function during fractioned irradiation.

Authors:  C Sagowski; S Wenzel; L Jenicke; F U Metternich; M Jaehne
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-11-12       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.